Natural Versus Artificial Cycle for Frozen-Thawed Embryo Transfer

Overview

This study evaluates clinical pregnancy rates, obstetrical outcome parameters, costs and patient preferences in natural cycle versus artificial cycle frozen embryo transfers (FET).

Full Title of Study: “Frozen-thawed Embryo Transfer in a Natural Versus Artificial Cycle: a Randomized Clinical Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 1, 2024

Detailed Description

Transfer of cryopreserved embryos can be performed in a natural cycle (NC-FET) or in an artificially prepared cycle (AC-FET). Both cycle regimens have their advantages and disadvantages. So far, most comparative studies have failed to identify the optimal protocol for FET. In this study patients undergoing FET will be randomized between an endometrial preparation by a natural cycle or by an artificial cycle (by oestradiol validate and micronized progesterone).

Interventions

  • Drug: Natural cycle
    • no medication
  • Drug: Estradiol Valerate
    • Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
  • Drug: Micronized progesterone
    • Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.

Arms, Groups and Cohorts

  • Experimental: Natural cycle
    • no medication
  • Active Comparator: Artificial cycle
    • Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy. Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.

Clinical Trial Outcome Measures

Primary Measures

  • Clinical pregnancy rate with fetal heart beat
    • Time Frame: 9 weeks
    • Clinical pregnancy rate with fetal heart beat diagnosed by ultrasound no later than the gestational age of 9 weeks

Secondary Measures

  • Biochemical pregnancy rate
    • Time Frame: 9 weeks
  • Miscarriage rate
    • Time Frame: 12 weeks
  • Ectopic pregnancy rate
    • Time Frame: 9 weeks
  • Live birth rate
    • Time Frame: 41 weeks
  • Multiple pregnancy rate
    • Time Frame: 9 weeks
  • Adverse events
    • Time Frame: 12 weeks
    • tombo-embolic events, serious side-effects (car leaflet) which require cancellation of treatment
  • Cycle cancellation rate
    • Time Frame: 4 weeks
  • Endometrial thickness
    • Time Frame: 3 weeks
  • Endometrial pattern
    • Time Frame: 3 weeks
    • Sonographic aspect of the endometrium (triple-line, no triple-line)
  • number of center visits to monitor FET cycle
    • Time Frame: From date of randomization until the date of the embryo transfer or until cancellation (estimated period of time up to 4 weeks)
  • cost analysis per treatment cycle
    • Time Frame: From date of randomization until the date of the embryo transfer or until cancellation (estimated period of time up to 4 weeks)
  • patient satisfaction
    • Time Frame: 12 weeks
    • To evaluate the effect of the different regimens on patients wellbeing/distress, Patient Reported Experience Measures (PREMS) from validated questionnaires will be used. Twenty-two questions from the Benyamini questionnaire will be used (Benyamini et al. 2005) and 10 questions from the subscales ‘environment’ (α=0.81) and ‘tolerability’ (α=0.75) of the FertilQol questionnaire (Pedro et al 2013). On the day of embryo transfer, the treating gynecologist will hand out the questionnaire to the patient. The patient will return the filled-in questionnaire on the day of the pregnancy test, before she knows the result of the pregnancy test.

Participating in This Clinical Trial

Inclusion Criteria

  • Women undergoing FET after a first, second or third fresh IVF/ICSI cycle – Single embryo transfer (SET) or Double embryo transfer (DET) – Female age between 18-45 year – Women having a natural ovulatory cycle (24-35 days) – Normal uterine cavity (fundal indentation at the cavity <10mm) – Written informed consent Exclusion Criteria:

  • Use of donor gametes – BMI > or equal to 35 kg / m2 – Any contra-indication to estrogen or progesterone supplementation (e.g. history of thrombosis, prior or current hormone-sensitive malignancy…)

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Universitaire Ziekenhuizen KU Leuven
  • Collaborator
    • GZA Ziekenhuizen Campus Sint-Augustinus
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.